TG Therapeutics

Quarterly Financials

Values in thousands2025-12-312025-09-302025-06-302025-03-31
Revenue
$192,574
$161,709
$141,148
$120,856
Gross Profit
154,365
133,554
122,210
105,315
EBITDA
51,693
32,692
37,695
12,281
EBIT
51,626
32,630
37,636
12,225
Net Income
23,037
390,895
28,187
5,060
Net Change In Cash
192,574
161,709
141,148
120,856
Free Cash Flow
19,593
-23,233
7,394
-28,740
Cash
79,148
74,081
129,126
132,139
Basic Shares
159,366
160,997
162,559
162,769

Annual Financials

Values in thousands2025-12-312024-12-312023-12-312022-12-31
Revenue
$616,287
$329,004
$233,662
$2,785
Gross Profit
515,328
290,518
219,531
2,520
EBITDA
134,361
49,902
26,100
-213,106
EBIT
134,117
49,622
25,677
-213,621
Net Income
447,179
23,383
12,672
-223,812
Net Change In Cash
616,287
329,004
233,662
2,785
Cost of Revenue
-196,574
Free Cash Flow
-24,986
-40,562
-31,413
-176,184
Cash
79,148
179,894
92,933
102,304
Basic Shares
161,412
160,336
148,508
135,411

Earnings Calls

QuarterEPS
2025-12-31
$0.14
2025-09-30
$2.43
2025-06-30
$0.17
2025-03-31
$0.03